Zhang C, Ma MH, Liang Y, Wu KZ, Dai DQ. Novel long non-coding RNA LINC02532 promotes gastric cancer cell proliferation, migration, and invasion in vitro. World J Gastrointest Oncol 2019; 11(2): 91-101 [PMID: 30788037 DOI: 10.4251/wjgo.v11.i2.91]
Corresponding Author of This Article
Dong-Qiu Dai, PhD, Professor, Department of Gastroenterological Surgery, The Fourth Affiliated Hospital of China Medical University, 4 Chongshan Road, Shenyang 110032, Liaoning Province, China. daidq63@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Basic Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Feb 15, 2019; 11(2): 91-101 Published online Feb 15, 2019. doi: 10.4251/wjgo.v11.i2.91
Novel long non-coding RNA LINC02532 promotes gastric cancer cell proliferation, migration, and invasion in vitro
Cheng Zhang, Ming-Hui Ma, Yu Liang, Kun-Zhe Wu, Dong-Qiu Dai
Cheng Zhang, Ming-Hui Ma, Yu Liang, Kun-Zhe Wu, Dong-Qiu Dai, Department of Gastroenterological Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang 110032, Liaoning Province, China
Author contributions: Dai DQ and Zhang C designed the study; Zhang C, Liang Y, Ma MH, and Wu KZ performed the experiments and data analysis; Zhang C wrote the paper.
Supported byNational Natural Science Foundation of China, No. 30572162; and Natural Science Foundation of Liaoning Province, No. 201602817.
Institutional review board statement: The study was approved by the Clinical Research Ethics Committee of the Fourth Affiliated Hospital of China Medical University (approved number: EC-2016-KS-028) and was performed according to the standards of the International Conference on Harmonisation-Good Clinical Practice (ICH-GCP).
Conflict-of-interest statement: None.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Dong-Qiu Dai, PhD, Professor, Department of Gastroenterological Surgery, The Fourth Affiliated Hospital of China Medical University, 4 Chongshan Road, Shenyang 110032, Liaoning Province, China. daidq63@163.com
Telephone: +86-24-62043110 Fax: +86-24-62043110
Received: November 12, 2018 Peer-review started: November 14, 2018 First decision: December 7, 2018 Revised: December 22, 2018 Accepted: January 8, 2019 Article in press: January 8, 2019 Published online: February 15, 2019 Processing time: 96 Days and 22.2 Hours
Core Tip
Core tip: Our study identified a novel long non-coding RNA LINC02532 and found that it was significantly overexpressed in gastric cancer (GC). Kaplan-Meier survival analysis showed that patients with higher LINC02532 expression had poorer prognosis than those with lower LINC02532 expression. The correlation analysis between expression and clinicopathological features revealed that the high expression of LINC02532 was associated with a high TNM stage and poor differentiation grade. Functional assays supported the finding that LINC02532 promoted GC cell proliferation, migration, and invasion. According to the bioinformatics analysis, LINC02532 may sponge downregulated miR-129-5p and miR-490-5p and participate in transcriptional misregulation in cancer, cell cycle, and TGF-beta, mTOR, and p53 signaling pathways.
